CoSyne Therapeutics is a hub-and-spoke biotech focused on rare neurological diseases. They acquire late-stage clinical assets and position them in genetically defined patient populations, creating highly de-risked, fast-to-approval programs.

Due to limited availability, we will not be meeting with CROs/CDMOs this year at BIO.